VERTEX PHARMACEUTICALS INCORPORATED Funds and ETFs Vertex Pharmaceuticals Incorporated
Equities
VRTX
US92532F1003
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 422.8 USD | +0.90% |
|
+5.41% | +3.91% |
| May. 10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
| May. 07 | FOMO is Back |  |
ETFs positioned on Vertex Pharmaceuticals Incorporated
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 0 M€ | +3.63% | - |
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
2024-05-15
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
422.8
USD
Average target price
462.1
USD
Spread / Average Target
+9.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B | |
| +295.70% | 8.12B |
- Stock Market
- Equities
- VRTX Stock
- Funds and ETFs Vertex Pharmaceuticals Incorporated